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The purpose of this study was to determine whether diﬀerent types of resistant starch (RS) elicited diﬀerent glycemic responses.
Eleven healthy subjects consumed solutions containing 30 g of either dextrose (DEX), resistant starch type 2 (RS2), or cross-linked
resistant wheat starch type 4 (RS4XL) on three separate occasions, which were assigned randomly. Finger stick blood samples were
collected before and over the following two hours and measured for glucose. The incremental area under the curve (iAUC) for the
glucose response was calculated for all trials. The two types of resistant starch significantly (P < .05) decreased iAUC compared
with DEX. The response with RS4XL was significantly decreased compared with the RS2 trial. These data demonstrate that diﬀerent
types of resistant starch elicit significantly diﬀerent glycemic responses.
1. Findings
Foods containing resistant starch (RS) generally give a low
glycemic response because RS is not digested in the small
intestine. Instead RS passes into the large intestine where
it is fermented [1–8]. Starch can escape digestion if it is
embedded in a matrix that renders the starch inaccessible to
enzymes (type 1, RS1). In addition, some untreated starch
granules are known to resist digestion (RS2). Again, starch
which is cooked and cooled, nongranular, and sometimes
debranched, forms RS when it reassociates and recrystallizes
(RS3). Finally, starches that are structurally modified become
resistant (RS4).
Examples of RS2 also include untreated granules of
potato, green bananas, and high-amylose maize starches.
When boiled in water, potato, and banana starches lose their
resistance, but high-amylose maize starch, being diﬃcult to
cook, partially retains granular structure and resistance to
digestion. Hydrothermal treatment of high-amylose maize
starch enhances its level of RS [7, 9]. Examples of RS4
are cross-linked starches [10–12], starch esters [13], starch
ethers, [14] and pyrodextrins with new glycosidic linkages
diﬀering from alpha-1, 4 and alpha-1, 6 bonds [7, 15].
The swelling and solubilities of RS2 from high-amylose
(70%) maize starch and RS4XL are much lower than normal
cereal starches in both cold and hot water [11, 16, 17].
At 95◦C in excess water RS4XL showed a swelling power
of 2.8 g/g and solubility of 0.5% compared to untreated
wheat starch at 7.6 g/g and 27.7% [17]. Hydrothermally
treated high-amylose (70%) maize starch (Novelose 240,
which contains less RS than Novelose 260) did not change
granular structure when heated in water up to 85◦C [16], and
it showed a swelling power at 95◦C of 2.1 g/g and solubility
of 1.9% [17].
Most clinical trials to date have used RS2 as the ingredient
of choice for studies investigating the glucose lowering
potential of RS. There is a paucity of research on the clinical
outcomes of other types, especially RS4. Wheat-derived
RS4XL may have greater potential at decreasing the glucose
response as it contains a high degree of dietary fiber and
RS [18], but there has only been one clinical trial testing
its eﬃcacy at lowering blood glucose [19]. Furthermore,
there are limited, if any, studies that have compared the
health outcomes of various types of RS, which makes it
diﬃcult to fully understand the beneficial capacity of RS to
assist with glucose control. Thus, the aim of this clinical
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trial (NCT00930956; ClinicalTrials.gov) was to determine
whether RS2 (the most commonly tested type of RS) and
RS4XL elicit similar glucose responses.
2. Research Design and Methods
The volunteers (females n = 7, males n = 4; age = 24± 4 yr;
ht = 1.65 ± 0.07 m; wt = 63.7 ± 13.1 kg; BMI = 23.2 ±
3.8 kg/m2) were not diagnosed with any chronic disease.
The Institutional Review Board of Kansas State University
approved the study, and all volunteers provided written
informed consent.
Each volunteer visited the laboratory in a 10–12 hour
fasted state on three occasions over a three-week period,
up to two visits/wk, with at least 48 hours between visits.
Volunteers were asked to refrain from vigorous physical
activity and the consumption of alcohol the day before each
testing visit. Randomization using a Latin Square design was
applied to minimize confounding issues associated with the
order of administration. Each volunteer consumed 30 g of
carbohydrate in the following forms: 178 mL of a dextrose
beverage (DEX; Sun-Dex); resistant starch type 2 diluted in
178 mL of water (RS2; Hi-Maize 260); cross-linked resistant
wheat starch diluted in 178 mL of water (RS4XL; Fibersym
RW). The dose was established from a prior study showing
improved insulin sensitivity using RS2 [20]. The use of the
DEX treatment was to provide a reference from which to
compare the other treatments, and allow for determining a
relative glycemic response.
In the morning of each test, finger-prick capillary blood
samples were collected to determine fasting (baseline) blood
glucose levels. The volunteers then consumed the test
solution assigned for that trial. Ten minutes were allowed
for the test solution to be consumed. Over the two hours
following the start of each test, finger-prick capillary blood
samples were collected at 30, 60, 90, and 120 minutes. Blood
glucose levels were immediately measured in duplicate using
an automated blood glucose analyzer (YSI 2300, Yellow
Springs, Ohio, USA). Analysis of the collected sample was
repeated if the diﬀerence between duplicate samples was
greater than 0.1 mmol/L. Once the samples were analyzed,
the data was entered and the incremental area under the
curve was calculated using the trapezoidal model (GraphPad
v5.0, La Jolla, Calif, USA).
Statistical Analysis. Paired t-tests were used to determine
significant diﬀerences between treatments at each time
point and to determine diﬀerences between iAUC values;
significance was set at P = .05. The data was statistically
analyzed using SPSS software (v13.0; Chicago, Ill, USA).
3. Results
The numerical peak in glucose for the DEX and RS2
treatments occurred at 30 minutes, while the glucose peak
during the RS4XL treatment did not occur until 120 minutes
(Figure 1(a)). The iAUC for each treatment was diﬀerent
from one another (Figure 1(b)). The DEX trial elicited an
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Figure 1: The glucose responses to 30 g of carbohydrate from three
treatments (DEX, RS2 and RS4XL). Panel (a) depicts the glucose
changes over time, while panel (b) depicts the incremental area
under the glucose curve. Data presented are mean±SE; significance
was set at P < .05; and, diﬀerent letters indicate diﬀerence between
treatments.
increased iAUC compared with RS2 (P = .001) and RS4
(P = .000), while the iAUC for RS2 was increased compared
with RS4XL (P = .002). The relative glycemic responses were
100%, 34.9 ± 11%, and 11.3 ± 10% for DEX, RS2, and
RS4XL, respectively.
4. Conclusions
This randomized clinical study demonstrates that diﬀerent
types of RS elicit diﬀerent glycemic responses. This study
supports prior studies where RS attenuated the glucose
response [19–25], as both types of RS in the present study
attenuated the glucose response compared with the same
amount dextrose. However, these data indicate that not all RS
types elicit similar glucose responses, as the RS4XL response
was less than RS2. A reason for this observation is likely
that RS4XL contains a greater degree of dietary fiber (91.9%)
and more RS (83%) [18] compared with the fiber (60%)
and RS content (46%) of the version of RS2 that was used
[26]. This is a critical application issue since companies use
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these functional starches as ingredients in food products.
As an ingredient, these results indicate that based on a
weight comparison, the RS4XL elicits a greater capacity to
attenuate the glucose response. Additionally, it has previously
been demonstrated that RS4XL attenuates blood glucose and
insulin responses when incorporated in food [19].
This study is limited by the fact that the volunteers
consumed the ingredients as is which this is not the form
that these ingredients are typically consumed. However, to
determine glucoregulatory diﬀerences between types of RS,
this approach of direct unprocessed comparison is necessary
to determine how processing or cooking can aﬀect the level of
RS remaining in a food [18]. Future studies should compare
other types of raw RS to determine which oﬀers the greatest
glucose lowering potential. Additionally, these diﬀerent types
need to be compared in typical food applications. All in all,
both types of RS elicited a lower blood glucose response in
vivo; however, the type of RS needs to be considered because
the glucose lowering capacity can diﬀer significantly.
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